Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- Describing the Sex-Specific Distribution of CAC Scores in South Asian Adults in the United StatesSouth Asian individuals living in the United States (SAUS) have an increased risk of atherosclerotic cardiovascular disease (ASCVD), most of which can be attributed to a relatively higher prevalence of traditional risk factors, potentially occurring at an earlier age than in other racial and ethnic groups.
- CVD Risk Scores, CV Health Metrics Predict Greater Cancer RiskWorse cardiovascular disease risk scores or cardiovascular health metrics predict greater cancer risk, despite heterogeneity in cardiovascular disease risk metrics and cancer types, according to a study published July 15 in JACC: CardioOncology.
- SUMMIT Analysis: Does BMI and Central Adiposity Affect Tirzepatide Outcomes For HFpEF?Although tirzepatide showed no heterogeneity in primary cardiovascular outcomes for differing baseline BMI or central adiposity, individuals with heart failure (HF) with preserved ejection fraction (HFpEF) with higher BMI at baseline showed greater improvement in six-minute walking distance...
- ACCEL Lite: Hypertension Diagnosis and Management: Renal Denervation and Newer Agents on the HorizonIn this interview, Dr. Alison L. Bailey and Dr. Keith C. Ferdinand explore the evolving landscape of hypertension management, highlighting new evidence supporting the benefits of tight blood pressure control across diverse populations.
- 18F Flurpiridaz PET MPI: New Horizons in Cardiac ImagingFluorine-18 (18F) flurpiridaz is a radiotracer for positron emission tomography (PET) myocardial perfusion imaging (MPI) newly approved by the Food and Drug Administration (FDA), offering several advantages due to its favorable physical properties.